PowderMed was founded in May 2004 to develop the proprietary Particle Mediated Epidermal Delivery (PMED^TM) technology. PMED delivers DNA vaccines into the skin without needles in a dry powder formulation of microscopic gold particles. These particles are accelerated to high speed by helium gas in the hand held PMED device and propelled into the epidermal layer of the skin. This needle-free delivery mechanism is ideally suited to the delivery of DNA vaccines as the epidermis contains a powerful network of immune cells acting as the body’s primary barrier against infection.

PowderMed was acquired by Pfizer in 2006, and the PMED technology is being used in a number of Pfizer vaccine programmes. In December 2008 the PowderMed site in Oxford was closed down, following the completion of technology transfer into Pfizer. For all enquires regarding business connected to PowderMed please contact the following:

For financial enquires specific to PowderMed please telephone Pfizer personnel on: +44 (0) 1304 646033

For all other enquiries relevant to PowderMed please telephone Pfizer personnel on: +44 (0) 1304 642095

For the Pfizer website please click here Pfizer Inc.